Not yet recruiting
Systemic lupus erythematosus+6
Not yet recruitingStudy of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments
Registered drugNo placebo
Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments
Registered drugNo placebo
- Disease:Systemic lupus erythematosusRheumatoid arthritis+5
- Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01ERESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
Countries:
Sweden
Sweden- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
- Sponsor:Region Skane